Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.79) per share for the quarter.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.23. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Sagimet Biosciences Stock Down 3.9%
SGMT opened at $3.18 on Wednesday. Sagimet Biosciences has a 12-month low of $1.73 and a 12-month high of $7.38. The business has a 50 day moving average of $3.08 and a 200-day moving average of $4.20. The stock has a market cap of $97.55 million, a price-to-earnings ratio of -1.81 and a beta of 2.32.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $32.00 price target on shares of Sagimet Biosciences in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.40.
Get Our Latest Analysis on Sagimet Biosciences
About Sagimet Biosciences
(
Get Free Report)
Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sagimet Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.
While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
